-
Forward Look
Telling the TaleQ&A with medical oncologist Siddhartha Mukherjee, the Pulitzer Prize-winning author of The Emperor of All Maladies.
by Sue Rochman
-
Forward Look
The Proof of the Proton Is in the ResultProton beam radiation therapy is expensive and controversial.
by Stephen Ornes
-
Forward Look
The Whole BeanStudies present a mixed picture of coffee's influence on cancer risk.
by Yvonne Lee
-
Forward Look
Melanoma Indoor Tanning Link ConfirmedTeens and young adults face heightened risk from tanning beds.
by Yvonne Lee
-
Forward Look
A Paycheck Linked to Cancer?Studies on workplace exposures show continued health risks.
by Corinna Wu
-
When Cancer Rings TwiceOne out of every six people diagnosed with cancer this year will be facing it for, at least, the second time.
by Melissa Weber
-
Changing the Face of Clinical TrialsEfforts are under way to increase African-American enrollment in cancer clinical trials.
by Leslie Harris O'Hanlon
-
Of Mice and MarriageFor more than three decades, cancer geneticists Neal Copeland and Nancy Jenkins have been a team both inside and outside the lab.
by Stephen Ornes
-
Missing the MarkOnly one-third of new cancer therapies or drug combinations tested in phase III clinical trials prove to be better than the standard of care. Researchers explain why and how they are aiming to improve the odds.
by Sue Rochman
-
Healthy Habits
Going With the GrainA fiber-rich diet can reduce cancer risk.
by Alanna Kennedy-Gorman
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
